Form 4: Viking Therapeutics Director Rouan Acquires 1,240 Shares
SEC Form 4 Filing
Director Sarah Kathryn Rouan purchased 1,240 shares of Viking Therapeutics (VKTX) at a price of $24.1474 per share on March 31, 2025.
Summary
- On March 31, 2025, Sarah Kathryn Rouan, a director of Viking Therapeutics, Inc. (VKTX), acquired 1,240 shares of common stock.
- The purchase price was $24.1474 per share.
- Following the transaction, Ms. Rouan directly owns 1,240 shares of Viking Therapeutics.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It reflects a routine insider transaction. The purchase could be interpreted as a positive signal, but without additional context, it's difficult to gauge the overall impact.
Positives
- A director's purchase of company stock can be seen as a positive signal, indicating confidence in the company's future prospects.
Industry Context
Insider transactions are closely monitored by investors as they can provide insights into a company's performance and management's confidence.
Stakeholder Impact
- The purchase could have a minor positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 03/31/2025 | Date of transaction: Sarah Kathryn Rouan purchased 1,240 shares of VKTX. |
| 04/02/2025 | Date of signature on the Form 4 filing. |
Keywords
Viking Therapeutics, VKTX, insider trading, Form 4, stock purchase, director, Sarah Kathryn Rouan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.